Comparison of three neoadjuvant chemotherapy in treating cervical carcinoma
10.3760/cma.j.issn.1673-4904.2010.30.010
- VernacularTitle:三种新辅助化疗在宫颈癌治疗中近期作用的比较
- Author:
Qian ZHONG
;
Wanmin LIU
;
Xiaoqin LIAN
;
Haiqing WANG
;
Weijian ZHANG
;
Fang LIU
;
Baoning WEN
- Publication Type:Journal Article
- Keywords:
Antineoplastic combined chemotherapy protocols;
Uterine cervical neoplasms;
Treatment outcome
- From:
Chinese Journal of Postgraduates of Medicine
2010;33(30):23-25
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the application value of neoadjuvant chemotherapy (NACT) in treating cervical carcinoma. Methods Seventy-one cervical carcinoma patients who were divided into three groups:PF group (cisplatin and fluorouracil,23 cases) or CBP group (carboplatin,bleomycetin and cyclophosphamide, 24 cases) or TP group (paclitaxel and cisplatin, 24 cases); operation was made 14 - 21 days afterwards. The therapeutic effect, chemotherapy side-effect and the effect on operation and pathology for these three groups were analyzed and compared. Results The effective rate was 93.8%(30/32),88.6% (31/35),82.4%(28/34) in TP group,CBP group,PF group,respectively. However, the therapeutic effect had no statistics significance with age, preoperative tumor grade, pathologic type for all the three groups, the therapeutic effect had statistical significance with clinical stage. The rate which pathological examination showed no residual cancer was biggest in CBP group [CBP group was 28.6%(6/21), TP group was 4.3% (1/23), PF group was 11.8%(2/17), P < 0.05 ]. Conclusions Three NACT projects are safe and effective treatment for cervical cancer. However,each project has advantages. The NACT projects can be elected for different patient according to his illness and economy.
